Company Overview and News

8
Tetraphase: A Strong Player In The Antibiotic Resistance Field

2018-10-04 seekingalpha - 1
Xerava (eravacycline), the only drug for cIAI treatment that has a broad spectrum coverage, has just received FDA and EMA approvals.
MTFBF TTPH AGN AZN NBRV TBPH NVS MTFB MTFB LLY BMY

5
NBRV / Nabriva Therapeutics AG DEF 14A

2018-10-01 sec.gov - 2
Use these links to rapidly review the document TABLE OF CONTENTS
NBRV

3
Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

2018-09-25 globenewswire
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer, will provide a company overview and business update at the Cantor Fitzgerald Global Healthcare Conference on Monday, October 1, 2018 at 8:20 a.
NBRV

9
NBRV / Nabriva Therapeutics AG 8-K/A (Current Report)

2018-09-10 sec.gov - 6
UNITED STATES<
NBRV

4
NBRV / Nabriva Therapeutics AG PRE 14A

2018-09-10 sec.gov - 1
Use these links to rapidly review the document TABLE OF CONTENTS
NBRV

3
NBRV / Nabriva Therapeutics AG / Wellington Management Group LLP - SEC SCHEDULE 13G (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Nabriva Therapeutics plc (Name of Issuer) Common Stock (Title of Class of Securities) G63637105 (CUSIP Number)
NBRV

3
NBRV / Nabriva Therapeutics AG / Wellington Management Group LLP - SEC SCHEDULE 13G (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Nabriva Therapeutics plc (Name of Issuer) Common Stock (Title of Class of Securities) G63637105 (CUSIP Number)
NBRV

4
NBRV / Nabriva Therapeutics AG 10-Q (Quarterly Report)

2018-08-09 sec.gov - 1
Table of Contents
NBRV

3
3
Nabriva Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

2018-08-08 globenewswire
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer, will provide a company overview and business update at the 2018 Wedbush PacGrow Healthcare Conference on Wednesday, August 15, 2017 at 10:55 a.
NBRV

3
3
NBRV / Nabriva Therapeutics AG / Longitude Capital Partners II, LLC - SC 13G (Passive Investment)

2018-08-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NBRV

3
NBRV / Nabriva Therapeutics AG / Longitude Capital Partners II, LLC - SC 13G (Passive Investment)

2018-08-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NBRV

NBRV: Nabriva Therapeutics AG Analysis and Research Report

2018-08-23 - Asif

Overview Nabriva Therapeutics is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections. Nabriva Therapeutics has two product candidates that are in late stage development: lefamulin, under development to potentially be the first pleuromutilin antibiotic available for systemic administration in humans, and CONTEPO, a potentially first-in-class epoxide intravenous, or IV, antibiotic in the United States. Nabriva Therapeutics is developing both IV and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia, or CABP. Nabriva Therapeutics is developing CONTEPO IV for complicated urinary tract infections, or cUTI. The company may potentially develop lefamulin and CONTEPO for additional indications. On July 24, 2018, the company completed the acquisition, or the Acquisition, of Zavante Therapeutics, Inc., or Zavante, a privately-held late clinical-stage biopha...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 62957M104